CoChat

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth

Open access
Casara, Patrick, Davidson, James, Claperon, Audrey, Le Toumelin-Braizat, Gaëtane, Vogler, Meike, Bruno, Alain, Chanrion, Maïa, Lysiak-Auvity, Gaëlle, Le Diguarher, Thierry, Starck, Jérôme-Benoît, Chen, Ijen, Whitehead, Neil, Graham, Christopher, Matassova, Natalia, Dokurno, Pawel, Pedder, Christopher, Wang, Youzhen, Qiu, Shumei, Girard, Anne-Marie, Schneider, Emilie, Gravé, Fabienne, Studeny, Aurélie, Guasconi, Ghislaine, Rocchetti, Francesca, Maïga, Sophie, Henlin, Jean-Michel, Colland, Frédéric, Kraus-Berthier, Laurence, Le Gouill, Steven, Dyer, Martin J.S., Hubbard, Roderick, Wood, Mike, Amiot, Martine, Cohen, Gerald M, Hickman, John A., Morris, Erick, Murray, James, Geneste, Olivier · 2018 · Oncotarget
Cited by 118

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

// Patrick Casara 1, * , James Davidson 2, * , Audrey Claperon 3, * , Gaëtane Le Toumelin-Braizat 3 , Meike Vogler 4 , Alain Bruno 5 , Maïa Chanrion 3 , Gaëlle Lysiak-Auvity 3 , Thierry Le Diguarher 1 , Jérôme-Benoît Starck 1 , Ijen Chen 2 , Neil Whitehead 2 , Christopher Graham 2 , Natalia Matassova 2 , Pawel Dokurno 2 , Christopher Pedder 2 , Youzhen Wang 6 , Shumei Qiu 6 , Anne-Marie Girard 3 , Emilie Schneider 3 , Fabienne Gravé 3 , Aurélie Studeny 3 , Ghislaine Guasconi 3 , Francesca Rocchetti 3 , Sophie Maïga 7 , Jean-Michel Henlin 1 , Frédéric Colland 3 , Laurence Kraus-Berthier 5 , Steven Le Gouill 7 , Martin J.S. Dyer 8 , Roderick Hubbard 2 , Mike Wood 2 , Martine Amiot 7 , Gerald M Cohen 9 , John A. Hickman 3 , Erick Morris 6 , James Murray 2 and Olivier Geneste 3 1 Institut de Recherches Servier Discovery Chemistry Unit, Croissy Sur Seine, France 2 Vernalis (R&D) Ltd., Cambridge, UK 3 Institut de Recherches Servier Oncology R&D Unit, Croissy Sur Seine, France 4 Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Frankfurt, Germany 5 Institut de Recherches Internationales Servier, Oncology R&D Unit, Suresnes, France 6 Novartis Institute of Biomedical Research, Oncology Drug Discovery, Cambridge, MA, USA 7 CRCINA, INSERM, CNRS, Université de Nantes, CHU de Nantes, Nantes, France 8 Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester, UK 9 Institute of Translational Medicine, University of Liverpool, Liverpool, UK * These authors contributed equally to this work Correspondence to: Olivier Geneste, email: olivier.geneste@servier.com Keywords: BCL-2; inhibitor; BH3-mimetics; apoptosis; hematological malignancies Received: September 12, 2017 Accepted: February 26, 2018 Published: April 13, 2018 ABSTRACT Escape from apoptosis is one of the major hallmarks of cancer cells. The B-cell Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins that are key regulators of the apoptotic process. Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia. Thus, BCL-2 has become an attractive target for therapeutic strategy in cancer, as demonstrated by the recent approval of ABT-199 (Venclexta™) in relapsed or refractory Chronic Lymphocytic Leukemia with 17p deletion. Here, we describe a novel orally bioavailable BCL-2 selective and potent inhibitor called S55746 (also known as BCL201). S55746 occupies the hydrophobic groove of BCL-2. Its selectivity profile demonstrates no significant binding to MCL-1, BFL-1 (BCL2A1/A1) and poor affinity for BCL-XL. Accordingly, S55746 has no cytotoxic activity on BCL-XL-dependent cells, such as platelets. In a panel of hematological cell lines, S55746 induces hallmarks of apoptosis including externalization of phosphatidylserine, caspase-3 activation and PARP cleavage. Ex vivo , S55746 induces apoptosis in the low nanomolar range in primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples. Finally, S55746 administered by oral route daily in mice demonstrated robust anti-tumor efficacy in two hematological xenograft models with no weight lost and no change in behavior. Taken together, these data demonstrate that S55746 is a novel, well-tolerated BH3-mimetic targeting selectively and potently the BCL-2 protein.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.24744

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 118

Metadata

Authors
Casara, P., Davidson, J., Claperon, A., Le Toumelin-Braizat, G., Vogler, M., Bruno, A., Chanrion, M., Lysiak-Auvity, G., Le Diguarher, T., Starck, J.-B., Chen, I., Whitehead, N., Graham, C., Matassova, N., Dokurno, P., Pedder, C., Wang, Y., Qiu, S., Girard, A.-M., Schneider, E., Gravé, F., Studeny, A., Guasconi, G., Rocchetti, F., Maïga, S., Henlin, J.-M., Colland, F., Kraus-Berthier, L., Le Gouill, S., Dyer, M. J. S., Hubbard, R., Wood, M., Amiot, M., Cohen, G. M., Hickman, J. A., Morris, E., Murray, J., & Geneste, O.
Venue
Oncotarget
Published
2018-04-13
Volume
9
Issue
28
Pages
20075-20088
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2793766280
Cited by
118
References
12
FWCI
4.47
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.